Medplus Health Services to host earnings call on Jul 22

medplus health services will host an earnings call on July 22, 2026, at 16:00 IST to discuss the audited financial results for the quarter ended June 30, 2026. The event is being held pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Schedule

The company has scheduled the analysts and institutional investors meet to review the performance for the period. The call will be hosted by Medplus Health Services Limited, and participants can access the event through pre-registration or direct dial-in options.

Event	Date and Time	Medium
Earnings Call	Wednesday, July 22, 2026, at 16:00 Hrs. (IST)	Hosted by the Company

Access Details

Participants can join the conference via two methods. The first option involves pre-registering through a specific link to join without waiting for an operator. Alternatively, attendees can use the provided dial-in numbers, available both domestically and internationally, by connecting 10 minutes prior to the scheduled start time.

Universal dial-in numbers include +91 22 6280 1267 and +91 22 7115 8223. International toll-free access is provided for various regions including the USA, UK, Australia, Canada, Japan, Singapore, and several European and Asian nations. For assistance, participants may contact 040-6724 6724.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.90%	-1.19%	-7.32%	-3.28%	-8.21%	-28.02%

Optival Health Solutions Private Limited, a subsidiary of medplus health services , has received suspension orders for drug licenses at three of its stores located in Karnataka. The orders were issued by the Assistant Director of the Drugs Control Administration in Bangalore Circle-3 and Belgaum Circle. The company disclosed that the suspensions were imposed due to violations under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The financial impact is estimated at a total potential revenue loss of ₹1.59 lakh.

The first order involves the suspension of the drug license for one day for a store situated at the Sarakki JP Nagar Metro Station. The second order also suspends the license for one day for a store located in Jaraganahalli. Both orders were received from the Bangalore Circle-3 authority. The third order, received from the Belgaum Circle authority, suspends the drug license for two days for a store situated at K C Road Chikkodi.

The following table details the specific actions taken and the estimated financial impact:

Authority	Nature of Action	Date of Receipt	Violation	Potential Revenue Loss
Assistant Director, Drugs Control Administration, Bangalore Circle-3, Karnataka	Suspension of Drug License for one day (Sarakki JP Nagar Metro Station)	14.07.2026	Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Rs 0.77 lacs
Assistant Director, Drugs Control Administration, Bangalore Circle-3, Karnataka	Suspension of Drug License for one day (Jaraganahalli)	-	Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Rs 0.35 lacs
Assistant Director, Drugs Control Administration, Belgaum Circle, Karnataka	Suspension of Drug License for two days (K C Road Chikkodi)	-	Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Rs 0.47 lacs

The disclosure was made in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Gangadi Madhukar Reddy, Managing Director and Chief Executive Officer of Medplus Health Services Limited. The information is available on the company's website and the exchanges.